CDKN2B Gene Multiple Endocrine Neoplasia Type 1 NGS Genetic DNA Test
Understanding CDKN2B Gene Testing for MEN1 Syndrome
The CDKN2B Gene Multiple Endocrine Neoplasia Type 1 NGS Genetic DNA Test represents a cutting-edge diagnostic approach for identifying hereditary cancer predisposition. Multiple Endocrine Neoplasia Type 1 (MEN1) is an autosomal dominant disorder characterized by tumors in multiple endocrine organs, primarily affecting the parathyroid glands, pancreatic islet cells, and anterior pituitary gland. This comprehensive genetic analysis utilizes Next-Generation Sequencing technology to detect mutations in the CDKN2B gene, which plays a crucial role in cell cycle regulation and tumor suppression.
What This Test Measures and Detects
This advanced genetic test specifically targets the CDKN2B gene, which encodes the p15 protein – a critical tumor suppressor involved in cell cycle regulation. The test identifies:
- Pathogenic variants and mutations in the CDKN2B gene
- Single nucleotide polymorphisms (SNPs) associated with MEN1 risk
- Copy number variations affecting gene function
- Novel genetic alterations impacting tumor suppressor activity
- Inheritance patterns for family risk assessment
Who Should Consider CDKN2B Genetic Testing?
This test is particularly recommended for individuals presenting with:
- Family history of Multiple Endocrine Neoplasia Type 1
- Early-onset hyperparathyroidism (before age 30)
- Multiple endocrine tumors in different organs
- Pancreatic neuroendocrine tumors
- Pituitary adenomas with associated hormonal imbalances
- Unexplained endocrine disorders affecting multiple glands
- First-degree relatives of confirmed MEN1 patients
Clinical Symptoms and Indications
Patients experiencing symptoms such as recurrent kidney stones, unexplained hypoglycemia, visual field defects, galactorrhea, or Cushing’s syndrome should consider genetic testing. Additionally, individuals with diagnosed endocrine tumors in multiple locations warrant comprehensive genetic evaluation to rule out hereditary syndromes.
Benefits of CDKN2B Genetic Testing
- Early Risk Identification: Detect genetic predisposition before symptom onset
- Personalized Surveillance: Develop targeted screening protocols based on genetic risk
- Family Planning Guidance: Inform reproductive decisions and family risk assessment
- Proactive Management: Implement preventive measures and early interventions
- Treatment Optimization: Guide therapeutic decisions based on genetic profile
- Psychological Relief: Provide clarity and reduce uncertainty for at-risk individuals
Understanding Your Test Results
Test results are typically categorized as:
- Positive Result: Indicates the presence of a pathogenic CDKN2B mutation, confirming MEN1 diagnosis and necessitating regular surveillance
- Negative Result: No mutation detected, though clinical monitoring may still be recommended based on family history
- Variant of Uncertain Significance (VUS): Requires additional family studies and clinical correlation
- Benign Polymorphism: Common genetic variation not associated with disease risk
Test Specifications and Pricing
| Test Component | Details |
|---|---|
| Test Name | CDKN2B Gene Multiple Endocrine Neoplasia Type 1 NGS Genetic DNA Test |
| Discount Price | $500 USD |
| Regular Price | $700 USD |
| Turnaround Time | 3 to 4 Weeks |
| Sample Type | Blood, Extracted DNA, or One Drop Blood on FTA Card |
| Testing Method | Next-Generation Sequencing (NGS) |
Pre-Test Requirements and Genetic Counseling
Before testing, patients must provide comprehensive clinical history and participate in genetic counseling sessions. Our certified genetic counselors will:
- Create detailed pedigree charts documenting family members affected by MEN1
- Explain test implications, benefits, and limitations
- Discuss potential psychological impacts of test results
- Provide guidance on insurance coverage and privacy considerations
- Help interpret results within the context of personal and family medical history
Nationwide Accessibility
We maintain comprehensive testing facilities across the United States, with branches in all major metropolitan areas including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, and San Jose. Our network ensures convenient access to cutting-edge genetic testing services regardless of your location.
Take Control of Your Genetic Health Today
Don’t wait to understand your genetic risk for Multiple Endocrine Neoplasia Type 1. Our specialized CDKN2B genetic testing provides the clarity needed for informed healthcare decisions. With advanced NGS technology and expert genetic counseling support, you can proactively manage your health and protect future generations.
Ready to schedule your test? Call or WhatsApp us today at +1(267) 388-9828 to book your appointment or speak with our genetic specialists. Take the first step toward comprehensive genetic health assessment and personalized medical management.
